Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board
29 Luglio 2021 - 6:00PM
Onxeo
S.A. (Euronext Growth Paris: ALONX, Nasdaq
First North: ONXEO), « Onxeo », a clinical-stage
biotechnology company specializing in the development of innovative
drugs targeting tumor DNA Damage response (DDR) in oncology, today
announced the appointment of Dr Shefali Agarwal as the Company’s
Chairwoman of the Board of Directors. Danièle Guyot-Caparros,
outgoing Chairwoman, remains an independent member of the Board of
Directors and Chair of the Audit Committee.
Dr. Shefali Agarwal, physician by training, is
the Chief Medical and Development Officer at Epizyme, Inc, which
develops novel epigenetic therapies for cancer and other serious
diseases, where she leads global clinical development and
regulatory strategy. Prior to joining Epizyme in 2018, Dr. Agarwal
held leadership positions including clinical development and
operations, and medical and regulatory affairs. In particular, she
led for Tesaro, the clinical development and registration of the
PARP inhibitor ZEJULA® (niraparib) in ovarian cancer.
In addition, Dr. Agarwal is a member of the
Board of Directors of three U.S. biotechnology companies, ITB Med
(private), Gritstone Bio and Fate Therapeutics. She was appointed
as an independent director of Onxeo in June 2021.
Shefali Agarwal,
incoming
Chairwoman of the Board
of Directors of Onxeo, comments: "I am very honored to be
appointed with this new role on the Board of Directors of Onxeo and
would like to thank all its members for the trust they have placed
in me. I have been impressed by the innovative science and unique
platform of Onxeo as well as by the management team. I look forward
to sharing my experience in global development to the benefit of
the Company’s promising pipeline and bringing innovative and
effective medicine to cancer patients in need”.
Danièle
Guyot-Caparros, outgoing
Chairwoman,
added: "The Company is preparing to take a new strategic step, with
the implementation of an ambitious clinical program and a
reinforced presence in the United States. I am convinced that Dr.
Agarwal's expertise and in-depth knowledge of the global biotech
world will be a real asset for Onxeo and I look forward to
continuing to support Onxeo in achieving its ambitious goals.”
Judith Greciet, Chief Executive Officer
of Onxeo, concludes: "I would like to acknowledge Danièle
Guyot-Caparros' remarkable contribution to Onxeo since 2013, the
year she was first appointed as a Director. During her tenure,
Danièle has supported the Company in the realization of several
major structural operations and I am delighted to continue to
benefit from her support on the Board of Directors. The appointment
of Dr. Shefali Agarwal as Chair marks a new stage in the
development of Onxeo, resolutely focused on creating value through
the clinical demonstration of the interest of our approach to
DDR."
About Onxeo
Onxeo (Euronext Paris, NASDAQ
Copenhagen: ONXEO) is a clinical-stage biotechnology company
developing innovative oncology drugs targeting tumor DNA-binding
functions through unique mechanisms of action in the sought-after
field of DNA Damage Response (DDR). The Company is focused on
bringing early-stage first-in-class or disruptive compounds from
translational research to clinical proof-of-concept, a
value-creating inflection point appealing to potential
partners.
platON™ is
Onxeo’s chemistry platform of oligonucleotides acting as decoy
agonists, which generates new innovative compounds and broaden the
Company’s product pipeline.
AsiDNA™, the
first compound from platON™, is a first-in-class, highly
differentiated clinical stage candidate in the field of DNA Damage
Response (DDR). Its decoy and agonist mechanism acting upstream of
multiple DDR pathways results in distinctive antitumoral
properties, notably the ability to prevent or abrogate tumor
resistance to targeted therapies such as PARP inhibitors and a
strong synergy with tumor DNA-damaging agents such as
radio/chemotherapy. AsiDNA™ is currently in combination clinical
studies in hard-to-treat solid tumors.
OX401 is a new drug candidate
from platON™, optimized to be a potent PARP agonist acting on both
the DNA Damage Response and the activation of immune response,
without inducing resistance. OX401 is undergoing preclinical
proof-of-concept studies, alone and in combination with
immunotherapies.
For more
information, please visit
www.onxeo.com.
Forward looking statementsThis
communication expressly or implicitly contains certain
forward-looking statements concerning Onxeo and its business. Such
statements involve certain known and unknown risks, uncertainties
and other factors, which could cause the actual results, financial
condition, performance or achievements of Onxeo to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is
providing this communication as of this date and does not undertake
to update any forward-looking statements contained herein as a
result of new information, future events or otherwise. For a
discussion of risks and uncertainties which could cause actual
results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements,
please refer to the risk factors described in the most recent
Company’s registration document or in any other periodic financial
report and in any other press release, which are available free of
charge on the websites of the Company Group (www.onxeo.com) and/or
the AMF (www.amf-france.org).
Contacts
Onxeo |
Media Relations |
Investor Relations / Strategic Communication |
Valerie
Leroy, |
Nicolas Merigeau |
Dušan
Orešanský / Emmanuel Huynh |
Investor
Relations |
NewCap |
NewCap |
investors@onxeo.com |
onxeo@newcap.eu |
onxeo@newcap.eu |
+33 1 45
58 76 00 |
+33 1 44 71 94 98 |
+33 1 44 71
94 92 |
Certified Adviser for
Nasdaq First NorthKapital
Partnerwww.kapitalpartner.dkinfo@kapitalpartner.dk+45 89 88 78
46